Stero Biotechs

Clinical-stage company developing CBD-based treatment solutions to enhance steroid therapy and reduce side effects.

Health Tech & Life Sciences
Active
Seed Bnei Brak, Israel Founded 2017
Last updated 2026-07-20
Total raised
$1.0M
Last: Undisclosed Round 2019-03
Stage
Seed
Founded
2017
Headcount
3
HQ
Bnei Brak, Israel
Sector
Health Tech & Life Sciences

About

Stero Biotechs Ltd., founded in 2017 and headquartered in Israel, is a clinical-stage company committed to the research and development of novel Cannabidiol (CBD) based treatment solutions. The company's focus is on enhancing the therapeutic effect of steroid treatments, allowing for more effective treatments, reduced dosages, and fewer side effects. Stero Biotechs holds a U.S. patent covering the use of CBD for steroid sparing in over 130 autoimmune and inflammatory diseases. The company was established in partnership with Mor Research Applications, the technology transfer unit of Clalit Health Services, the largest HMO in Israel. In March 2020, Kalytera Therapeutics announced its intention to acquire Stero Biotechs for $30 million, but the acquisition did not proceed.

Funding history · 1 round · $1.0M total

2019-02
Undisclosed Round $1.0M

Headcount over time

From 2 (2019-10) to 2 (2022-06) · +0 (+0%) · 8 points · source: Finder history + radar grounding
70 2019-10 2022-06

Q&A

What is Stero Biotechs' primary focus?
Stero Biotechs is a clinical-stage company that researches and develops CBD-based treatment solutions to reduce the side effects and need for steroid therapy.
When was Stero Biotechs founded?
Stero Biotechs was founded in February 2017.
What is the employee count for Stero Biotechs?
Stero Biotechs has 1-10 employees.
What is Stero Biotechs' total funding to date?
Stero Biotechs has raised a total of $1,000,000 USD.
When did Stero Biotechs complete its last funding round?
Stero Biotechs completed its last funding round in March 2019.
What clinical trials has Stero Biotechs commenced?
Stero Biotechs commenced phase 2a clinical trials for steroid-dependent Crohn's disease in Q1 2020 and for chronic urticaria in Q3 2020. Additionally, a phase 1/2 clinical trial for severe COVID-19 patients started in Q1 2021.
Who is the CEO of Stero Biotechs?
David Bassa is the CEO and a founder of Stero Biotechs.
Is Stero Biotechs involved in any partnerships?
Stero Biotechs was established in partnership with Mor Research Applications, the technology transfer unit of CLALIT Health Services.

Team · 1

David Bassa
Founder · Founder & CEO

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyMedical Cannabis
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 Patents

Tags

autoimmune-diseasesanti-inflammatorybiotechnologydrug-deliverycannabismedical-cannabisinflammatory-diseasescrohn-s-diseaserespiratorytreatmentsdermatology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitesterobiotechs.com
LinkedInlinkedin.com/company/15807532

Identifiers & details

Legal nameSTERO BIOTECHS LTD
Founded2017-2
Employees (exact)3

Radar intelligence

Patents

EPO4

Web history (Wayback)

Domainsterobiotechs.com

Certificate / subdomain footprint

Subdomains8

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)515604460
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2017-02-06
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2026
Active charges / liens0
Registry events1 — annual_report (1)
Registered addressבר כוכבא 23 בני ברק

Recent registry events

DateEvent
2026-01-26דו~ח שנתי